Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01424657
Other study ID # REC. 97-026
Secondary ID
Status Terminated
Phase Phase 3
First received August 23, 2011
Last updated August 26, 2011
Start date October 1997
Est. completion date July 2002

Study information

Verified date August 2011
Source McGill University Health Center
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug AdministrationCanada: MUHC Research Ethics Board
Study type Interventional

Clinical Trial Summary

The main objective of this study is to assess the effectiveness and costs of magnetic resonance cholangiopancreatography (MRCP) and compare it to endoscopic retrograde cholangiopancreatography (ERCP) in the work up of patients with suspected bile duct obstruction on ultrasound. The investigators do not anticipate that a universal recommendation for a given diagnostic test (MRCP versus ERCP) will be applicable in all patients presenting with bile duct obstruction. Rather, the investigators hope to provide quantitative and comparative data relevant to the different clinical situations likely to be encountered in practice, in order to assist physicians in choosing the appropriate diagnostic modality. More specifically, the investigators feel that patients with intrahepatic or hilar obstruction (particularly those with malignant conditions), and those with partial common bile duct (CBD) obstruction (to rule out suspected choledocholithiasis) will benefit most from this new technology and the avoidance of an unnecessary ERCP to further determine the biliary anatomy.


Description:

The approach to investigation and management of intermediate-risk biliary obstruction is controversial. Both magnetic resonance cholangiopancreatography(MRCP)and endoscopic retrograde cholangiopancreatography (ERCP) are used interchangeably in practice, with little literature to support the efficacy of one versus the other.

The purpose is to assess the effectiveness of MRCP compared to ERCP in the initial work-up of patients at intermediate risk of suspected biliary obstruction following initial clinical assessment and ultrasonography.

A randomized medical effectiveness study was conducted across three tertiary care hospital sites. Patients at intermediate risk of biliary obstruction were randomized to either ERCP or MRCP based on level of obstruction as seen by ultrasound (US).


Recruitment information / eligibility

Status Terminated
Enrollment 378
Est. completion date July 2002
Est. primary completion date July 2002
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Age greater than 18 years

- Elevated bilirubin (>30 umol/L)

- CBD dilatation on ultrasound: greater than 7 mm wide with gallbladder in situ, or 10mm wide in patient post-cholecystectomy

- Suspected or detected gallstone on ultrasound

Exclusion Criteria:

- Low probability of biliary tract disease

- Active cholangitis

- Bilio-pancreatic pathology identified on ultrasound or CT scan

- Any clinical condition precluding MRCP or ERCP: severe cardio-respiratory disease, pregnancy, significant coagulopathy (INR over 1.5)

- Presence of Roux-en-Y bilio-enteric anastomosis

- Any metallic implant making ERCP or MRCP hazardous

- ERCP or MRCP performed within 6 months prior to study inclusion

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Procedure:
ERCP
Endoscopic retrograde cholangiopancreatography
MRCP
magnetic resonance cholangiopancreatography

Locations

Country Name City State
Canada MUHC- McGill University Health Center Montreal Quebec

Sponsors (5)

Lead Sponsor Collaborator
McGill University Health Center Alberta Heritage Foundation for Medical Research, American College of Gastroenterology, American Digestive Health Foundation, Canadian Institutes of Health Research (CIHR)

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary occurrence of adverse biliary events The goal of this study was to evaluate the effectiveness of MRCP compared to ERCP in assessment of patients at intermediate risk for suspected biliary obstruction 12 months No
Secondary complication-related length of stay 12 months Yes
Secondary Number of additional procedures (i.e ERCP, MRCP, US...) 12 months No
Secondary mortality 12 months No